Onabotulinumtoxin A Injections for Patients With Pelvic Floor Dysfunction.
Abstract
[STUDY OBJECTIVE] To review the current literature surrounding onabotulinum toxin A injections for patients with pelvic floor dysfunction and to show how to perform these injections.
[SETTING] Academic tertiary care hospital DESIGN: It is estimated that about 50% to 90% of patients with chronic pelvic pain have pain that originates from myofascial sources, including the pelvic floor muscles. In patients with pelvic floor dysfunction, management consists of pelvic floor physical therapy with the addition of pelvic floor trigger point injections with a local anesthetic as needed. We offer onabotulinum toxin A to individuals who require long-term repeat trigger point injections, have barriers to accessing monthly injections, or show no durable improvement.
[INTERVENTION] We show a comprehensive pelvic floor exam and techniques for administering of onabotulinum toxin A to pelvic floor muscles in individuals with pelvic floor dysfunction, as well as a demonstration on a live patient. We perform an exam while the patient is awake, either in the clinic or at the time of the procedure, and examine the pubococcygeus, iliococcygeus, and obturator internus muscles to assess for hypertonicity and tenderness to palpation. Once sedation is initiated, 200 units of onabotulinum toxin A are then reconstituted with 20 mL of normal saline. The pudendal nerve kit allows for 1 cm depth of penetration with the needle. Approximately 1 to 2 mL of onabotulinumtoxin A are injected sequentially in multiple locations along the above-mentioned pelvic floor muscles. Medication effects may last up to 3 to 6 months, with a reduction in pain scores starting at 6 weeks and lasting through 12 weeks based on published literature. Adverse effects may include constipation, urinary incontinence, urinary tract infections, fecal incontinence, or urinary retention.
[CONCLUSIONS] Onabotulinumtoxin A may be helpful in patients with refractory pelvic floor dysfunction. We show how to perform these injections with a safe and reproducible technique.
[VIDEO ABSTRACT] Video: Onabotulinumtoxin A may be helpful in patients with refractory pelvic floor dysfunction, and we demonstrate how to perform these injections safely.
[SETTING] Academic tertiary care hospital DESIGN: It is estimated that about 50% to 90% of patients with chronic pelvic pain have pain that originates from myofascial sources, including the pelvic floor muscles. In patients with pelvic floor dysfunction, management consists of pelvic floor physical therapy with the addition of pelvic floor trigger point injections with a local anesthetic as needed. We offer onabotulinum toxin A to individuals who require long-term repeat trigger point injections, have barriers to accessing monthly injections, or show no durable improvement.
[INTERVENTION] We show a comprehensive pelvic floor exam and techniques for administering of onabotulinum toxin A to pelvic floor muscles in individuals with pelvic floor dysfunction, as well as a demonstration on a live patient. We perform an exam while the patient is awake, either in the clinic or at the time of the procedure, and examine the pubococcygeus, iliococcygeus, and obturator internus muscles to assess for hypertonicity and tenderness to palpation. Once sedation is initiated, 200 units of onabotulinum toxin A are then reconstituted with 20 mL of normal saline. The pudendal nerve kit allows for 1 cm depth of penetration with the needle. Approximately 1 to 2 mL of onabotulinumtoxin A are injected sequentially in multiple locations along the above-mentioned pelvic floor muscles. Medication effects may last up to 3 to 6 months, with a reduction in pain scores starting at 6 weeks and lasting through 12 weeks based on published literature. Adverse effects may include constipation, urinary incontinence, urinary tract infections, fecal incontinence, or urinary retention.
[CONCLUSIONS] Onabotulinumtoxin A may be helpful in patients with refractory pelvic floor dysfunction. We show how to perform these injections with a safe and reproducible technique.
[VIDEO ABSTRACT] Video: Onabotulinumtoxin A may be helpful in patients with refractory pelvic floor dysfunction, and we demonstrate how to perform these injections safely.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 시술 | onabotulinumtoxin
|
보툴리눔독소 주사 | dict | 4 | |
| 해부 | Pelvic Floor
|
scispacy | 1 | ||
| 해부 | pubococcygeus
|
scispacy | 1 | ||
| 해부 | iliococcygeus
|
scispacy | 1 | ||
| 해부 | obturator internus muscles
|
scispacy | 1 | ||
| 해부 | urinary tract
|
scispacy | 1 | ||
| 합병증 | pelvic floor
|
scispacy | 1 | ||
| 약물 | Onabotulinumtoxin A
|
C2719767
onabotulinumtoxinA
|
scispacy | 1 | |
| 약물 | [STUDY OBJECTIVE]
|
scispacy | 1 | ||
| 약물 | saline
|
scispacy | 1 | ||
| 약물 | urinary
|
scispacy | 1 | ||
| 약물 | [CONCLUSIONS] Onabotulinumtoxin A
|
scispacy | 1 | ||
| 질환 | constipation
|
C0009806
Constipation
|
scispacy | 1 | |
| 질환 | urinary incontinence
|
C0042024
Urinary Incontinence
|
scispacy | 1 | |
| 질환 | urinary tract infections
|
C0042029
Urinary tract infection
|
scispacy | 1 | |
| 질환 | fecal incontinence
|
C0015732
Fecal Incontinence
|
scispacy | 1 | |
| 질환 | Pelvic Floor Dysfunction
|
C4041537
Pelvic floor dysfunction
|
scispacy | 1 | |
| 질환 | chronic pelvic pain
|
C0404484
Chronic pelvic pain of female
|
scispacy | 1 | |
| 질환 | pain
|
C0030193
Pain
|
scispacy | 1 | |
| 질환 | tenderness
|
C0234233
Sore to touch
|
scispacy | 1 | |
| 기타 | Patients
|
scispacy | 1 | ||
| 기타 | pelvic floor
|
scispacy | 1 | ||
| 기타 | onabotulinum toxin A
|
scispacy | 1 | ||
| 기타 | patient
|
scispacy | 1 | ||
| 기타 | pudendal nerve kit
|
scispacy | 1 |
MeSH Terms
Humans; Botulinum Toxins, Type A; Female; Pelvic Floor Disorders; Neuromuscular Agents; Injections, Intramuscular; Pelvic Pain; Pelvic Floor
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- Local therapeutic strategies for neurocutaneous dysesthesia: from capsaicin to cannabinoids.
- Comparative efficacy of intralesional therapies for keloid scars: a network meta-analysis.
- Adverse neurological events following botulinum toxin type A: A case series of post-injection seizures and paralysis.
- Decreased utilization of component separation techniques over time in complex abdominal wall reconstruction following introduction of preoperative botulinum toxin A.
- Current Perspectives on Pectoralis Minor Syndrome: A Narrative Review.